Author: Rob Stafford / Editor:Tajek B Hassan / Reviewer: Emma Everitt / Codes: CAP17, HAP17, CAP25, HAP23 / Published: 05/10/2018 Review Date: 05/10/2021
It is important for the emergency physician to consider phaeochromocytoma as part of a differential diagnosis, firstly because an acute crisis can be life threatening and secondly because timely diagnosis can enable complete curative surgical intervention. Autopsy studies have shown that phaeochromocytomas are often missed .
Phaeochromocytomas are rare neuroendocrine tumours that arise from either adrenal medulla or extra adrenal chromaffin tissue.
Incidence and Epidemiology
The spontaneous presentation of phaeochromocytoma is normally between the age of 40 and 50 years, however the hereditary forms often present in younger individuals, including children .
About 15% of phaeochromocytomas are extra-adrenal . Surgical treatment can effectively cure phaeochromocytoma in 90% of cases .
Phaeochromocytoma is associated with Von Hippel Landau disease, multiple endocrine neoplasia type 2 syndromes and neurofibromatosis type 1 .
Basic Science and Pathophysiology
The manifestations of phaeochromocytoma are due mostly to the increased abnormal secretion of catecholamines, principally epinephrine, but also norepinephrine and dopamine.
The relative amounts of catecholamines secreted can differ between tumours and this determines the clinical picture. The catecholamines can also be released episodically.
There are several proposed mechanisms for this including direct pressure, medications and changes in tumour blood flow .
The effects of epinephrine and norepinephrine are caused by agonist activity at alpha and beta adrenoceptors and are detailed below :
- Glycogenolysis in liver and skeletal muscle
- Mobilisation of free fatty acids
- Increased serum lactate
- Stimulation of metabolic rate
- Increased force and rate of contraction of the heart
- Both cause vasoconstriction, but epinephrine dilates vessels in skeletal muscle and liver, normally leading to a decrease in overall systemic vascular resistance
- Increase in alertness and evokes feelings of anxiety and fear
- Rise in plasma glucose
Dopamine, when injected, produces renal and mesenteric vascular dilatation. It also has positive inotropic effects and normally leads to an increase in systolic blood pressure.
Clinical features and presentation
The presenting features of phaeochromocytoma are very wide and varied. For this reason it is referred to as the great mimic.
Hypertension is a common presenting feature with systolic blood pressure above 220 mmHg or diastolic pressure above 120 mmHg being generally accepted limiting values. Hypertension is frequently associated with profound tachycardia, pallor and a feeling of anxiety or impending doom . These symptoms are often paroxysmal and can occur many times a month or just once with a single fatal presentation.
Precipitants can include abdominal compression, anaesthesia, opiates, dopamine antagonists, cold medications, radiographic contrast media, catecholamine reuptake inhibitors and childbirth [6,9].
Table 1: Other symptoms and signs [6,8].
|Orthostatic hypertensionHyperglycaemiaEpigastric pain |
Stigmata of neurofibromatosis
The diagnosis should be considered in any patient presenting with acute hypertension or with a hypertensive crisis but be aware that hypertension can be episodic or absent and consider the diagnosis if there is a syndrome of appropriate clinical features compatible with the diagnosis.
Differential diagnosis of Phaeochromocytoma [6,8]
The differential diagnosis of phaeochromocytoma, as discussed above, is wide and includes the conditions listed below:
- Medullary thyroid carcinoma
- Menopausal syndrome
- Heart failure
- Ischaemic heart disease
- Baroreflex failure
- Renovascular hypertension
- Diencephalic epilepsia
- Postural orthostatic tachycardia syndrome
- Essential hypertension
- Alcohol withdrawal
- Panic disorder or anxiety
- Factitious disorders
- Drug treatment
- Illegal drug use
Differential diagnosis of a hypertensive crisis
Phaeochromocytoma is a recognised cause of hypertensive crisis; other conditions which may cause a hypertensive crisis are listed below :
- Essential hypertension
- Renovascular hypertension
- Renal parenchymal disease
- Endocrine causes (Phaeochromocytoma, Cushings syndrome, hyperaldosteronism, thyrotoxicosis, hyperparathyroidism, acromegaly, adrenal carcinoma)
- Eclampsia and pre eclampsia
- Spinal cord injury
- Coarctation of the aorta
Investigation in the ED will be tailored to the patients presenting symptoms and signs and is usually directed at the more common conditions which phaeochromocytoma may mimic.
Investigation will usually include ECG, capillary blood glucose and FBC.
Phaeochromocytoma might mimic these common conditions:
- Acute coronary syndrome
- Subarachnoid haemorrhage
- Essential hypertension
- Anxiety/panic attacks
- Drug ingestion (e.g. cocaine)
Specific investigation for phaeochromocytoma is not usually instigated in the ED; appropriate subsequent tests include assay of plasma and urine metanephrines, catecholamines and urine vanillylmandelic acid (VMA).
The most sensitive test is plasma metanephrine assay (99% sensitivity with a specificity of 89%).
Initial imaging is usually CT scan of the abdomen (sensitivity 93-100%); MRI scanning has a similar sensitivity.
Definitive treatment is by surgical resection of the tumour, normally using a laparoscopic approach.
Prior to surgery the acute crisis is treated medically to control the effects of excess catecholamines. This is normally achieved by alpha adrenoceptor blockade.
Phenoxybenzamine is advocated as it blocks adrenoceptors irreversibly and therefore its effect cannot be overcome by increasing catecholamine concentrations. Phentolamine and Doxazosin are alternative alpha antagonists.
Phenoxybenzamine is used in the treatment of hypertensive crisis. The main action is vasodilatation by non-competitive antagonism of alpha adrenoceptors.
The dose by intravenous administration is 10-40 mg over one hour. It acts within one hour and its effects last for up to four days. It can be given orally in a dose of 10-60 mg/day in divided doses.
Side effects include hypotension, dizziness, sedation, dry mouth, paralytic ileus and impotence.
Phentolamine is used in the diagnosis and perioperative management of phaeochromocytoma. It causes vasodilatation, but also has positive inotropic and chronotropic effects. It exerts its effect predominantly by competitive alpha adrenoceptor blockade.
The adult intramuscular dose for control of acute paroxysmal hypertension is 5-10 mg.
Side effects include orthostatic hypotension, dizziness, abdominal discomfort and diarrhoea. Cardiovascular collapse has occurred following treatment of phaeochromocytoma.
Beta adrenoceptor blockade can be instituted to control tachycardia, but this should only be done after adequate alpha blockade, otherwise unopposed alpha activity can lead to worsening hypertension.
Patients may also require additional therapy to treat associated problems such as arrhythmias. Many patients require intravenous fluid as they are relatively fluid depleted. These additional therapies should be tailored on a case by case basis [3,5,6].
Beta blockade should not be used as sole therapy to control acute hypertension associated with phaeochromocytoma as unopposed alpha activity can lead to further increase in the blood pressure.
If phaeochromocytoma is suspected urgent discussion with an endocrinologist is advised.
Surgical resection is curative in 90% of cases.
Safety pearls and Pitfalls
- Although the disease is rare and can present in a wide variety of ways, there are several clinical characteristic markers that should alert the clinician to the potential diagnosis
- Autopsy studies have shown that phaeochromocytoma is first diagnosed at post mortem in about 50% of cases. Missing the diagnosis can deprive the patient of curative surgery
- Not all adrenal masses or elevations of catecholamines levels are due to phaeochromocytoma
- Platts JK, Drew PJ, Harvey JN. Death from phaeochromocytoma: lessons from a post-mortem survey. J R Coll Physicians Lond 1995;29(4):299-306.
- Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994;12(5):609-615.
- Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol 1992;147(1):1-10.
- Pacak K, Linehan WM, Eisenhofer G et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134(4):315-329.
- Neumann HP, Berger DP, Sigmund G et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993;329(21):1531-8. Erratum in: N Engl J Med 1994;331(22):1535.
- Sweeny A, Blake M, Melby J. Phaeochromocytoma. emedicine.medscape.com 2013. View article
- Ganong W. Review of Medical Physiology. 21st edn. Lange 2001.
- Ramrakha P, Moore K. Oxford Handbook of Acute Medicine. Oxford, 2004.
- Lenders JWM, Eisenhofer G, Mannelli M et al. Phaeochromocytoma. Lancet 2005;366(9486):665-675.
- Kearney T, Dang C. Diabetic and endocrine emergencies. Postgrad Med J 2007;83(976):79-86. Review.
- Zendron L, Fehrenbach J, Taverna C et al. Pitfalls in the diagnosis of phaeochromocytoma. BMJ 2004;328:629-630.
- Sanyal K, Fletcher S. Headache as a sign of phaeochromocytoma. Emerg Med J 2009;26:71.
- Cook RF, Katritsis D.Hypertensive crisis precipitated by a monoamine oxidase inhibitor in a patient with phaeochromocytoma. BMJ 1990;300(6724):614.
- Rosas AL, Kasperlik-Zaluska AA, Papierska L et al.Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. Eur J Endocrinol 2008;158(3):423-429.
- Sibal L, Jovanovic A, Agarwal SC et al. Phaeochromocytomas presenting as acute crises after beta blockade therapy. Clin Endocrinol (Oxf) 2006;65(2):186-190.
- Lyman DJ. Paroxysmal hypertension, pheochromocytoma, and pregnancy. J Am Board Fam Pract 2002;15(2):153-158.
- Kobal SL, Paran E, Jamali A et al. Pheochromocytoma: cyclic attacks of hypertension alternating with hypotension. Nat Clin Pract Cardiovasc Med 2008;5(1):53-57.
- Wu HW, Liou WP, Chou CC et al. Pheochromocytoma presented as intestinal pseudo-obstruction and hyperamylasemia. Am J Emerg Med 2008;26(8):971.
- Kizer JR, Koniaris LS, Edelman JD et al. Pheochromocytoma crisis, cardiomyopathy, and hemodynamic collapse. Chest 2000;118(4):1221-1223.
- Lassnig E, Weber T, Auer J et al. Pheochromocytoma crisis presenting with shock and tako-tsubo-like cardiomyopathy. Int J Cardiol 2009;134(3):e138-40.
- Moran ME, Rosenberg DJ, Zornow DH. Pheochromocytoma multisystem crisis. Urology 2006;67(4):846.e19-20.
- De Wilde D, Velkeniers B, Huyghens L et al. The paradox of hypotension and pheochromocytoma: a case report. Eur J Emerg Med 2004;11(4):237-239.
- Preuss J, Woenckhaus C, Schwesinger G et al. Non-diagnosed pheochromocytoma as a cause of sudden death in a 49-year-old man: a case report with medico-legal implications. Forensic Sci Int 2006;156(2-3):223-228.
- Sasada M, Smith S. Drugs in Anaestheisa & Intensive Care. 3rd edn. Oxford Medical Publications, 2003.
- Camacho PM, Gharib H, Sizemore GW. Evidence-based endocrinology. 2nd edn, revised. Lippincott Williams & Wilkins, 2006.